Skip to content
CFPS Research Archives

Semaglutide (Ozempic, Wegovy)

FDA-approved context Weight Loss & Metabolism 3 sources

Semaglutide is a long-acting GLP-1 receptor agonist that mimics the natural incretin hormone GLP-1. Extensive clinical research demonstrates its profound efficacy in improving glycemic control in type 2 diabetes and inducing substantial, sustained weight loss in individuals with obesity.

01Dosing reference

Amount
Prescription medication - dosing not provided
Frequency
Prescription medication - dosing not provided
Cycle
Prescription medication - dosing not provided
Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

01

GLP-1 Receptor Activation

Semaglutide binds to and activates the GLP-1 receptor, mimicking the action of the native GLP-1 hormone.

02

Metabolic Regulation

It stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying.

03

Appetite Suppression

It acts on appetite centers in the brain to increase feelings of fullness and reduce hunger, leading to decreased caloric intake.

03Human evidence

Achieved an average weight loss of ~15% of body weight over 68 weeks in adults with obesity or overweight.

STEP clinical trial program, involving large-scale, randomized, double-blind, placebo-controlled trials.

Significantly improved glycemic control and reduced the risk of major adverse cardiovascular events in patients with type 2 diabetes.

SUSTAIN clinical trial program, specifically the SUSTAIN-6 cardiovascular outcomes trial.

04Preclinical evidence

Reduced food intake and body weight by acting directly on the hypothalamus and hindbrain.

Diet-induced obese rodent models used to map central nervous system effects.

Demonstrated preservation of pancreatic beta-cell function and mass.

Diabetic animal models evaluating long-term disease-modifying potential.

05What is known vs. unknown

Reasonably established
  • Highly effective for chronic weight management and type 2 diabetes treatment.
  • Administered via once-weekly subcutaneous injection or daily oral tablet.
  • Provides cardiovascular benefits, reducing the risk of heart attack and stroke in specific populations.
  • Gastrointestinal side effects (nausea, vomiting, diarrhea) are common, particularly during dose escalation.
Unknowns & limits
  • Long-term effects of lifelong use on body composition, specifically muscle mass preservation.
  • Weight regain is highly likely if the medication is discontinued.
  • Rare potential risks such as pancreatitis or medullary thyroid carcinoma require ongoing post-marketing surveillance.

06Safety & regulatory context

Regulatory statusSemaglutide is FDA-approved for type 2 diabetes (as Ozempic and Rybelsus) and for chronic weight management (as Wegovy). The most common side effects are gastrointestinal, including nausea, diarrhea, vomiting, and constipation. It carries a boxed warning regarding the potential risk of thyroid C-cell tumors, based on findings in rodents, and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

07Compared with Tirzepatide

Semaglutide (Ozempic, Wegovy) vs. Tirzepatide
Key difference
Semaglutide is a single GLP-1 receptor agonist, whereas Tirzepatide is a dual GIP and GLP-1 receptor agonist.
When researchers discuss each
Semaglutide is discussed as the established, highly effective standard for GLP-1 therapy, while Tirzepatide is highlighted when discussing next-generation therapies offering potentially greater weight loss through dual-incretin action.

08Glossary

GLP-1 (Glucagon-like peptide-1)
A naturally occurring hormone that stimulates insulin secretion, inhibits glucagon release, and reduces appetite.
Incretin
A type of metabolic hormone released by the gut after eating that helps lower blood sugar levels.
Receptor Agonist
A substance that binds to a specific receptor on a cell and activates it to produce a biological response.

09Knowledge check

Q1What is the primary mechanism of action of Semaglutide?
Q2Which of the following is the most common side effect associated with Semaglutide use?
Q3Which of the following best describes a documented limitation of the semaglutide evidence in the supplied dossier?
Q4When researchers compare semaglutide and tirzepatide in the dossier, which characterization matches the stated comparison context?
Q5Which regulatory or safety statement about semaglutide is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism
Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism
Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism
Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug
Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.